Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 25, 2018
BioTime Licenses GMP Cell Line to Goliver Therapeutics
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...
June 25, 2018
ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes
RAMSEY, N.J. and BOCA RATON, Fla., June 25, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA), a vertically integrated commercial biopharmaceutical company that manufactures, markets ...
June 25, 2018
PolarityTE Added to Russell 3000® and Russell 2000® Indexes
SALT LAKE CITY, June 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of ...
June 25, 2018
Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
June 25, 2018
Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (FBIO) Company developing treatments for rare and life-threatening diseases, today ...
June 25, 2018
Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that additional data for Afrezza from the STAT study (STudy comparing prandial ...
June 25, 2018
Tyme Technologies, Inc. Set to Join Russell 3000® Index
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set ...
June 25, 2018
CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes
NEWARK, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
June 25, 2018
Catalyst Biosciences Joins the Russell 2000® Index
SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology ...
June 25, 2018
Albireo Added to Russell 2000® Index
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
June 25, 2018
MannKind Set to Join Russell 3000® Index
WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for ...
June 22, 2018
UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone® (idebenone) in Duchenne Muscular Dystrophy
Pratteln, Switzerland, June 22, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that the UK`s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed the Early Access to ...
June 22, 2018
Prometic Presents New Data on NASH Drug Candidate PBI-4547
LAVAL, QC, June 22, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced the presentation of four posters at the American Diabetes Association's 78th ...
June 22, 2018
Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss
MORRISTOWN, N.J., June 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced that Nalpropion Pharmaceuticals, Inc. (“Nalpropion”), the ...
June 22, 2018
Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass.
NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
June 22, 2018
Lilly Completes Acquisition of ARMO BioSciences
INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (ARMO). Lilly's ...
June 21, 2018
Molecular Templates Set to Join the Russell 3000® and Russell Microcap® Indexes
AUSTIN, Texas, June 21, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered ...
June 21, 2018
UPDATE - PolarityTE Appoints Paul Mann of Highbridge Capital to Chief Financial Officer
SALT LAKE CITY, June 21, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL) today announced that Paul Mann of Highbridge Capital Management is the new Chief ...
June 20, 2018
Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st
BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today ...
June 20, 2018
INVENTIVA : FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
Daix (France) June 20, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) ...
Page 30 of 117